ArticleBlood advances2018
Nivolumab-induced cold agglutinin syndrome successfully treated with rituximab.
Article in Blood advances, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors.American journal of hematology · 2019Trial
- Early-Onset Autoimmune Hemolytic Anemia from Pembrolizumab in a Patient with Metastatic Lung Cancer: A Case Report.The American journal of case reports · 2025Article
- Immune hemolytic anemia associated with the use of immune checkpoint inhibitors: a scoping review.Frontiers in immunology · 2025Article
- Diagnosis and management of cold agglutinin disease associated with low-grade B-cell lymphoma in a patient receiving pembrolizumab for lung cancer.BMJ case reports · 2021Article
- Management of Hematologic Adverse Events Associated With Immune Checkpoint Inhibitors.Journal of the advanced practitioner in oncology · 2021Article
- Pembrolizumab-Induced Cold Agglutinin Disease.The American journal of case reports · 2020Article
- Pembrolizumab-induced Pure Red Cell Aplasia Successfully Treated with Intravenous Immunoglobulin.Internal medicine (Tokyo, Japan) · 2020Article
- The role of B lymphocytes in the immuno-biology of non-small-cell lung cancer.Cancer immunology, immunotherapy : CII · 2020Review
- Novel insights into the treatment of complement-mediated hemolytic anemias.Therapeutic advances in hematology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.